MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

被引：0
|
作者：
Rubin, David
Pollack, Paul
Hunter, Theresa
Shan, Mingyang
Chan, Lai-Shan
Deckard, Deanilee
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [1] MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Rubin, David
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S14 - S15
  • [2] Mirikizumab Improves Patient Assessments of Disease Severity and Change in Disease Activity in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Travis, Simon
    Wu, Jianmin
    Sapin, Christophe
    Gibble, Theresa Hunter
    Hibi, Toshifumi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S30 - S31
  • [3] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    GASTROENTEROLOGY, 2022, 162 (03) : S15 - S15
  • [4] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S15 - S15
  • [5] MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Reguiro, Miguel D.
    Fischer, Monika
    Rubin, David T.
    Shan, Mingyang
    Deckard, Deanilee
    Pollack, Paul
    Hunter, Theresa
    Chan, Lai Shan
    Hindryckx, Pieter
    GASTROENTEROLOGY, 2021, 160 (06) : S354 - S355
  • [6] Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn's disease
    Blumenstein, I.
    Torres, J.
    Ma, C.
    Lindsay, J. O.
    Ungaro, R.
    Thin, L.
    Lacerda, A. P.
    Anyanwu, S. I.
    Garrison, A.
    Ford, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : II000 - I1001
  • [7] Improvement in fatigue with mirikizumab therapy is associated with improvements in patient-reported outcomes in patients with moderately to severely active Crohn's disease
    Reguiero, Miguel
    Fischer, Monika
    Rubin, David T.
    Hibi, Toshifumi
    Bossuyt, Peter
    Juillerat, Pascal
    Pollack, Paul
    Zhou, Xian
    Protic, Marijana
    Hunter, Theresa
    Chan, Lai Shan
    Carlier, Hilde
    Hindryckx, Pieter
    SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 27S
  • [8] Effect of 104 Weeks of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores Among Patients With Moderately to Severely Active Crohn's Disease
    Sands, Bruce E.
    Jairath, Vipul
    Gibble, Theresa Hunter
    Lin, Zhantao
    Traxler, Kristina
    Protic, Marijana
    Hozak, Rebecca
    Feagan, Brian G.
    Armuzzi, Alessandro
    Bossuyt, Peter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S809 - S809
  • [9] Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease
    Chua, L.
    Otani, Y.
    Friedrich, S.
    Durand, F.
    Zhang, X.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1873 - I1873
  • [10] Unemployment and disability in patients with moderately to severely active Crohn's disease
    Feagan, BG
    Bala, M
    Yan, S
    Olson, A
    Hanauer, S
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (05) : 390 - 395
12345